Safety & Efficacy of Denosumab in Chronic Kidney Disease Patients in Dubai Hospital: Single Center Experience
DOI:
https://doi.org/10.14738/bjhr.1303.2399Keywords:
Osteoporosis, Osteopenia, Denosumab, Chronic Kidney diseaseAbstract
Chronic kidney disease (CKD) patients has not only higher risk of bone fractures due to low bone mineral density & poor bone quality, but also carries high risk of cardiovascular disease due to soft tissue calcification in conjunction with secondary hyperparathyroidism and high phosphate. Bisphosphonates use was limited in CKD patients due to nephrotoxicity while Denosumab were found safe & effective. Purpose of study was to report efficacy & safety of denosumab in different stages of CKD, also to compare it with normal renal function patients. With help of medical software, data was collected for patients who received denosumab for osteoporosis, osteopenia or fragile fractures at least for 6 months. 90 patients were included (Osteoporosis 53.34%, fractures 25.56% & osteopenia 21.11%), 80% had CKD (Stage III: n=32,44.44%, Stage V: n=23, 31.94% & Stage IV n=11, 15.27%) while 20% had normal renal functions (NKF). CKD patients belonged to older age group than NKF patients (79±13 vs 73.06±13.63, p=<0.05). Osteoporosis (CKD vs NKF: 47.22% vs 77.78%, p<0.05) & Osteopenia (CKD vs NKF: 20.83% vs 22.22%, p >0.05) were more common in NKF patients, while fractures were more common in CKD patients (CKD vs NKF: 29.16% vs 11.11% p=>0.05). After denosumab therapy, there was not much improvement in osteopenia (pre & post in CKD: 20.83% vs 19.45%, p >0.05) or osteoporosis (pre & post 47.22% vs 45.80% p= >0.05) in CKD patients, while fracture frequency increased (pre & post in CKD: 29.16% vs 34.70%, p=>0.05) however these findings were not statistically significant. After Denosumab therapy, there was significant drop in median (IQR) corrected serum calcium {pre & post: 9.4(0.68) vs 9.2 (0.72), p<0.05}, while increase in parathyroid hormone {PTH pre & post: 46.5(74.77) vs 68.25(157.17), p<0.05) & 25 hydroxy vitamin D {pre & post denosumab: 28.50(17.65) vs 37.45(25.12), p<0.05} in CKD patients, whereas there was no significant change in phosphate. Positive effects of denosumab on BMD were not appreciated in our CKD population. Hypocalcemia is significant side effect and can be dealt with close monitoring, aggressive diet to provide calcium & vitamin D, awareness of doctors & health care professionals to set up integrated multidisciplinary care.
References
Bover J, Bailone L, López-Báez V, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017;30(5):677–687. doi:10.1007/s40620-017-0404-z.
Liu WC, Yen J-F, Lang C-L, et al. Bisphosphonates in CKD patients with low bone mineral density. Sci World J. 2013;2013(open in a new window):837573. doi:10.1155/2013/837573.
Moe SM. Renal Osteodystrophy or Kidney-Induced Osteoporosis? Curr Osteoporos Rep. 2017;15(3):194–197. doi:10.1007/s11914-017-0364-1.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95. doi: 10.1001/jama.285.6.785.
Khairallah P, Nickolas TL. Management of Osteoporosis in CKD. Clin J Am Soc Nephrol. 2018;13(6):962–969. doi:10.2215/CJN.11031017.
Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease. Intern Med. 2017;56(24):3271–3276. doi:10.2169/internalmedicine.8618-16. Scholar Publishing
Sessa C, Galeano D, Alessandrello I, et al. Osteoporosi e malattia renale cronica: vecchie e nuove strategie terapeutiche allo stato dell’arte [Osteoporosis and chronic kidney disease: review and new therapeutic strategies]. G Ital Nefrol. 2019;36:4. Italian.
Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004;34(5):881–889. doi: 10.1016/j.bone.2004.01.007.
Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765. doi: 10.1056/NEJMoa08094.
Moe SM, Drüeke TB, Block GA, et al. Kidney disease: improving global outcomes, CKDMBDUWG, KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59. doi: 10.1016/j.kisu.2017.04.001.
Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, et al. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65. doi: 10.1056/NEJMoa0809493.
Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized PlaceboControlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33:190-198. doi: 10.1002/jbmr.3337J.
Morizio P, Burkhart JI, Ozawa S. Denosumab: A Unique Perspective on Adherence and Costeffectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Ann Pharmacother. 2018;52:1031-1041. doi: 10.1177/1060028018768808.
Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153-61. doi: 10.1359/jbmr.0809010.
Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, et al. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2019;104:1753- 1765. doi: 10.1210/jc.2018-02236.
Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471–1479. doi: 10.1002/jbmr.1613 [DOI]
Jamal SA, Ljunggren Ö, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829–1835. doi: 10.1002/jbmr.403 [DOI]
Thongprayoon C, Acharya P, Acharya C, et al. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. 2018;29(8):1737–1745. doi: 10.1007/s00198-018-4533-6.
Bonani M, Frey D, Brockmann J, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16(6):1882–1891. doi: 10.1111/ajt.13692.
Festuccia F, Jafari MT, Moioli A, et al. Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol. 2017;30(2):271–279. doi: 10.1007/s40620-016-0334-1. Scholar Publishing
Iseri K, Watanabe M, Yoshikawa H, et al. Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. J Bone Miner Res. 2019;34(6):1014–1024. doi: 10.1002/jbmr.3676.
Kunizawa K, Hiramatsu R, Hoshino J, et al. Denosumab for dialysis patients with osteoporosis: a cohort study. Sci Rep. 2020;10(1):2496. doi: 10.1038/s41598-020-59143-8.
Nanmoku K, Shinzato T, Kubo T, et al. Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin Nephrol. 2019;92(1):1–8. doi: 10.5414/CN10972.
Smyth B, Ong S. Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction. Intern Med J. 2016;46(3):360–363. doi: 10.1111/imj.13001.
Cohen A, Chacko B. Severe hypocalcaemia following denosumab and iron infusion. Nephrology. 2022;27(9):781–782. doi: 10.1111/nep.14078.
Makras P, Polyzos SA, Papatheodorou A, et al. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol. 2013;79(4):499–503. doi: 10.1111/cen.12188.
Chen CH, Lo W-C, Hu P-J, et al. Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis. Front Pharmacol. 2022;13:822178. doi: 10.3389/fphar.2022.822178.
Nakamura Y, Kamimura M, Ikegami S, et al. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a shortterm study. BMC Endocr Disord. 2015;15(1):81. doi: 10.1186/s12902-015-0077-3
Chen CL, Chen N-C, Liang H-L, et al. Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass. J Clin Endocrinol Metab. 2015;100(7):2784–2792. doi: 10.1210/jc.2015-1259.
Cianciolo G, Tondolo F, Barbuto S, et al. Denosumab-induced hypocalcemia and hyperparathyroidism in de novo kidney transplant recipients. Am J Nephrol. 2021;52(8):611–619. doi: 10.1159/000518363.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 British Journal of Healthcare and Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
